Critical Outcome Technologies Inc. (COTI) is a Canada-based clinical-stage biopharmaceutical company. The Company uses machine learning to develop targeted therapies. The Company's business is disease-specific drug discovery, optimization and pre-clinical development using a developed series of computer models. Its artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds that are projected to have a high probability of being developed from disease specific drug discovery through chemical optimization and preclinical testing. The CHEMSAS platform technology is focused on small molecules, and as a drug candidate discovery engine can be applied to any disease. The Company is engaged in developing molecules through the preclinical testing stage as commercial validation of the CHEMSAS platform. COTI-2 is the Company's small molecule activator of misfolded mutant p53 protein.